Insmed Incorporated (INSM) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Insmed Incorporated (INSM) right now is BRINSUPRI as a potential blockbuster in a first-mover market: Brinsupri is the first and only approved treatment for non-cystic fibrosis bronchiectasis in the United States, European Union, and United Kingdom. Full-Year 2025 Revenue is ~$606 million. If that keeps playing out, the setup is favourable; the risk to it is the stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. No one can predict where INSM trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Insmed Incorporated (INSM) higher?
BRINSUPRI as a potential blockbuster in a first-mover market
Brinsupri is the first and only approved treatment for non-cystic fibrosis bronchiectasis in the United States, European Union, and United Kingdom. The Phase 3 ASPEN trial enrolled more than 1,700 patients and showed statistically significant reductions in annualized pulmonary exacerbations versus placebo. With list pricing around $88,000 per year, no boxed warnings in the prescribing label, and roughly 9,000 new patients initiating treatment in Q4 2025 alone, analysts have projected peak U.S. sales could approach $3.7 billion by 2031.
ARIKAYCE growth and label expansion potential
ARIKAYCE delivered approximately $425 million in full-year 2025 global revenue, reflecting consistent double-digit annual growth across the United States, Europe, and Japan. The Phase 3b ENCORE study met its primary and all multiplicity-controlled secondary culture conversion endpoints in early 2026, supporting a planned supplemental NDA filing in the second half of 2026 that could expand the label to newly diagnosed MAC lung disease patients, a substantially larger addressable population than the current refractory indication.
TPIP pipeline optionality in pulmonary hypertension
TPIP (treprostinil palmitil inhalation powder) is an inhaled dry-powder formulation being evaluated across multiple pulmonary hypertension settings, including PH-ILD, PAH, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. The Phase 3 PALM-PAH study initiated in April 2026, and Phase 2b data in PAH showed a placebo-adjusted 35% reduction in pulmonary vascular resistance and a 35.5-meter improvement on the six-minute walk test. Positive Phase 3 outcomes across these indications would represent a third meaningful revenue franchise.
Approaching profitability on dual-product revenue scale
Q1 2026 net loss narrowed 36% year-over-year to $163.6 million as total revenues surged 230% to $306.0 million. Analyst consensus projects the company to reach profitability around 2028, with forecast earnings of approximately $742 million that year. Revenue is expected to grow at roughly 34% annually over the next three years, well above the broader biotech industry forecast, as BRINSUPRI matures and ARIKAYCE expands.
What could weigh on INSM?
The stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. Pipeline execution risk is real: brensocatib failed its Phase 2b BiRCh study in chronic rhinosinusitis without nasal polyps in December 2025, demonstrating that indication expansion is not guaranteed. The company continues to operate at a net loss and has relied on equity offerings, including a $750 million share sale in June 2025, to fund its commercial and clinical build-out, creating ongoing dilution risk. Royalty obligations to AstraZeneca on BRINSUPRI sales and restrictive covenants in its debt and royalty financing agreements add financial complexity.
How to think about a INSM forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the INSM guide and whether INSM is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the INSM outlook
The bottom line: what is driving Insmed Incorporated (INSM) is BRINSUPRI as a potential blockbuster in a first-mover market, with full-year 2025 revenue at ~$606 million. If that keeps playing out the setup is favourable; the risk is the stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. No one can predict the price, so treat any INSM forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around INSM with Walnut
Use Insmed Incorporated as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Insmed Incorporated (INSM)?
+
No one can reliably predict where INSM will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Insmed Incorporated higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive INSM higher?
+
The main growth drivers are BRINSUPRI as a potential blockbuster in a first-mover market; ARIKAYCE growth and label expansion potential; TPIP pipeline optionality in pulmonary hypertension. Whether they play out is the real question, not a guaranteed path.
What are the risks to INSM?
+
The stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. Pipeline execution risk is real: brensocatib failed its Phase 2b BiRCh study in chronic rhinosinusitis without nasal polyps in December 2025, demonstrating that indication expansion is not guaranteed. The company continues to operate at a net loss and has relied on equity offerings, including a $750 million share sale in June 2025, to fund its commercial and clinical build-out, creating ongoing dilution risk. Royalty obligations to AstraZeneca on BRINSUPRI sales and restrictive covenants in its debt and royalty financing agreements add financial complexity.
Will INSM stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Insmed Incorporated's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is INSM a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the INSM "is it a buy?" page for a framework. Walnut is not an investment adviser.
What is Insmed's revenue outlook for 2026?
+
Insmed has guided for full-year 2026 BRINSUPRI revenues of at least $1 billion and ARIKAYCE revenues of $450 million to $470 million, which would imply total revenues of at least $1.45 billion for the year. Q1 2026 revenues of $306 million, with BRINSUPRI contributing $207.9 million, showed strong early progress toward that target. Analysts project revenue growing roughly 34% annually over the next three years on average.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.